Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $191.7 million.

  • Corcept Therapeutics' Total Liabilities rose 3182.67% to $191.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.7 million, marking a year-over-year increase of 3182.67%. This contributed to the annual value of $161.0 million for FY2024, which is 4019.79% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Total Liabilities stood at $191.7 million, which was up 3182.67% from $165.9 million recorded in Q2 2025.
  • Corcept Therapeutics' Total Liabilities' 5-year high stood at $191.7 million during Q3 2025, with a 5-year trough of $41.6 million in Q1 2021.
  • Its 5-year average for Total Liabilities is $101.5 million, with a median of $103.0 million in 2023.
  • In the last 5 years, Corcept Therapeutics' Total Liabilities plummeted by 91.54% in 2021 and then skyrocketed by 12097.31% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Total Liabilities stood at $47.9 million in 2021, then surged by 70.15% to $81.6 million in 2022, then soared by 40.72% to $114.8 million in 2023, then surged by 40.2% to $161.0 million in 2024, then increased by 19.1% to $191.7 million in 2025.
  • Its Total Liabilities stands at $191.7 million for Q3 2025, versus $165.9 million for Q2 2025 and $163.2 million for Q1 2025.